ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Harpoon Therapeutics Doses First Patient with Anti-DLL3 T Cell Engager for Lung Cancer
January 11, 2021Harpoon Therapeutics announced the first patient has been dosed with HPN328, a delta like ligand 3- (DLL3) targeting TriTAC®, in a Phase 1/2 clinical trial as an investigational treatment of small cell lung cancer (SCLC) and other tumors associated ...
Pharma Sources Insight January 2025
